11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S383000, C540S476000, C548S269400

Reexamination Certificate

active

10697547

ABSTRACT:
Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof:are selective inhibitors of the 11β-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidernia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

REFERENCES:
patent: 6849636 (2005-02-01), Waddell et al.
patent: WO 99/29674 (1999-06-01), None
patent: WO 00/07997 (2000-02-01), None
patent: WO 01/60802 (2001-08-01), None
patent: WO 01/90094 (2001-11-01), None
patent: WO 03/004497 (2003-01-01), None
Reimlinger et al., Chemische Berichte, vol. 103, No. 6, pp. 1960-1981 (1970), “Synthesis of s-triazolo[3,4-a]isoquinolines” (full text).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3850665

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.